Executive Director, AI/ML Drug Discovery Analytics

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$326K-$383K From the posting source

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$111,944 U.S. median for this role

Projected growth (BLS Employment Projections)

+13.7% - Much faster than average

217% above the BLS role benchmark for data and ml aggregate.

Posted salary is far from this role benchmark; treat it as low confidence.

Matched to SOC 15-1252 - Data and ML aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Data From the posting source

Seniority

Staff Plus From the posting source

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Equity

Offered Verified - SEC 10-K source

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Executive Director, AI/ML Drug Discovery Analytics Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As Executive Director, AI/ML Drug Discovery Analytics, you will be a senior leader shaping the future of data-driven drug discovery at Revolution Medicines. You will define the Research's AI/ML strategy, oversee implementation of advanced analytics across discovery and build a world-class team to unlock the full potential of our rich internal datasets and make these insights accessible to other scientist. Your leadership will directly influence early discovery innovation, pipeline acceleration, and strategic portfolio decisions. Responsibilities include: Technical Leadership and Innovation: You will have a deep understanding of Machine Learning Operations and AI system design. Design and scale a robust ML infrastructure, integrating MLOps best practices to ensure seamless development, deployment, and monitoring of AI/ML models. Drive innovation in applying deep learning, generative models, and diffusion models to drug discovery, including target prediction, hit identification, and lead optimization. Leverage RevMed's unique datasets

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.